These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 16293880)

  • 21. RARbeta2 is a candidate tumor suppressor gene in myelofibrosis with myeloid metaplasia.
    Jones LC; Tefferi A; Idos GE; Kumagai T; Hofmann WK; Koeffler HP
    Oncogene; 2004 Oct; 23(47):7846-53. PubMed ID: 15361842
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Myelofibrosis with myeloid metaplasia: the advanced phase of an untreated disseminated hematological cancer. Time to change our therapeutic attitude with early upfront treatment?
    Hasselbalch HC
    Leuk Res; 2009 Jan; 33(1):11-8. PubMed ID: 18632152
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bone changes in myelofibrosis with myeloid metaplasia: a histomorphometric and microcomputed tomographic study.
    Schmidt A; Blanchet O; Dib M; Baslé MF; Ifrah N; Chappard D
    Eur J Haematol; 2007 Jun; 78(6):500-9. PubMed ID: 17419743
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
    Zhan H; Spivak JL
    Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases.
    Panteli KE; Hatzimichael EC; Bouranta PK; Katsaraki A; Seferiadis K; Stebbing J; Bourantas KL
    Br J Haematol; 2005 Sep; 130(5):709-15. PubMed ID: 16115126
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quantitative analysis of growth factor production in the mechanism of fibrosis in agnogenic myeloid metaplasia.
    Wang JC; Chang TH; Goldberg A; Novetsky AD; Lichter S; Lipton J
    Exp Hematol; 2006 Dec; 34(12):1617-23. PubMed ID: 17157157
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Angiogenesis and anti-angiogenic therapy in myelofibrosis with myeloid metaplasia.
    Arora B; Mesa R; Tefferi A
    Leuk Lymphoma; 2004 Dec; 45(12):2373-86. PubMed ID: 15621750
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Idiopathic myelofibrosis: pathogenesis to treatment.
    Reilly JT
    Hematol Oncol; 2006 Jun; 24(2):56-63. PubMed ID: 16477581
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Experimental therapy in myelofibrosis with myeloid metaplasia.
    Verstovsek S; Quintás-Cardama A; Kantarjian H; Tefferi A
    Expert Opin Investig Drugs; 2006 Dec; 15(12):1555-63. PubMed ID: 17107281
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential expression of transforming growth factor-beta, basic fibroblast growth factor, and their receptors in CD34+ hematopoietic progenitor cells from patients with myelofibrosis and myeloid metaplasia.
    Le Bousse-Kerdilès MC; Chevillard S; Charpentier A; Romquin N; Clay D; Smadja-Joffe F; Praloran V; Dupriez B; Demory JL; Jasmin C; Martyré MC
    Blood; 1996 Dec; 88(12):4534-46. PubMed ID: 8977245
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
    Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
    Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The chronic Philadelphia chromosome-negative myeloproliferative syndrome I. Pathogenesis and pathophysiology].
    Hasselbalch HC; Mourits-Andersen HT; Jensen BA; Jensen MK; Nielsen OJ
    Ugeskr Laeger; 2001 Apr; 163(18):2471-3. PubMed ID: 11379259
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The therapy of myelofibrosis: targeting pathogenesis.
    Mesa RA
    Int J Hematol; 2002 Aug; 76 Suppl 2():296-304. PubMed ID: 12430941
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of bone morphogenetic proteins and their receptors in the bone marrow megakaryocytes of GATA-1(low) mice: a possible role in osteosclerosis.
    Garimella R; Kacena MA; Tague SE; Wang J; Horowitz MC; Anderson HC
    J Histochem Cytochem; 2007 Jul; 55(7):745-52. PubMed ID: 17371937
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Myelofibrosis: experimental models and human studies.
    Taskin AL; Cohen-Solal K; Le Couedic JP; Abina MA; Villeval JL; Debili N; Casadevall N; Vainchenker W; Wendling F
    Stem Cells; 1998; 16 Suppl 2():155-64. PubMed ID: 11012187
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders.
    Pikman Y; Levine RL
    Curr Opin Oncol; 2007 Nov; 19(6):628-34. PubMed ID: 17906464
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Properties of myelofibrosis-derived fibroblasts.
    Castro-Malaspina H; Jhanwar SC
    Prog Clin Biol Res; 1984; 154():307-22. PubMed ID: 6382300
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bone marrow immunohistochemical studies of angiogenic cytokines and their receptors in myelofibrosis with myeloid metaplasia.
    Chou JM; Li CY; Tefferi A
    Leuk Res; 2003 Jun; 27(6):499-504. PubMed ID: 12648509
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ultrastructure of bone marrow tissue in so-called primary (idiopathic) myelofibrosis-osteomyelosclerosis (agnogenic myeloid metaplasia). I. Abnormalities of megakaryopoiesis and thrombocytes.
    Thiele J; Kuemmel T; Sander C; Fischer R
    J Submicrosc Cytol Pathol; 1991 Jan; 23(1):93-107. PubMed ID: 2036630
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dysregulation and overexpression of HMGA2 in myelofibrosis with myeloid metaplasia.
    Andrieux J; Demory JL; Dupriez B; Quief S; Plantier I; Roumier C; Bauters F; Laï JL; Kerckaert JP
    Genes Chromosomes Cancer; 2004 Jan; 39(1):82-7. PubMed ID: 14603445
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.